Valneva SE filings document a foreign private issuer focused on prophylactic vaccines for infectious diseases. Its Form 6-K reports and Form 20-F disclosures cover consolidated financial results, product sales, research collaboration revenue, and business updates for marketed vaccines and clinical-stage programs, including Lyme disease, Shigella and chikungunya vaccine activities.
The filing record also includes material-event disclosures incorporated by reference into Form F-3 registration statements. These documents address material agreements, licensing and collaboration arrangements, capital-structure actions, shareholder voting and governance matters, risk factors, and clinical or regulatory updates for Valneva's vaccine candidates and commercial portfolio.
Valneva SE (VALN) announced that it will report its nine-month 2026 consolidated financial results and host a live webcast. The announcement gives conflicting dates: the headline states November 24, 2026, while the body says Tuesday, November 4, 2026. The webcast is scheduled for 3 p.m. CET/9 a.m. ET, will include a business update, and will be archived on the company's website after it ends.
Valneva SE announced that senior management will present and meet with institutional investors at upcoming healthcare conferences in the United States and Europe. The schedule includes a virtual group presentation in Paris and events in Boston, New York and London. Fireside chats will address the company’s value drivers and upcoming catalysts, particularly the regulatory outlook for its Lyme disease vaccine candidate, which is partnered with Pfizer; regulatory decisions are expected within the next 12 months.
Management will also discuss R&D pipeline progress and potential future value creation if the candidate is successfully approved and commercialized by Pfizer. A webcast replay will be available in the Investor section of Valneva’s website following the live events.
Valneva SE (VALN) announced that the UK Medicines and Healthcare products Regulatory Agency revoked IXCHIQ’s UK marketing authorization after the Commission on Human Medicines’ further benefit-risk assessment for travelers. Valneva said the decision followed a review of previous safety data and was not associated with a newly identified safety signal; the revocation does not affect the vaccine’s licenses in the EU, Canada, Brazil or other territories where it is marketed.
Valneva expects no expense related to product recall and only minimal impact on overall sales revenue, citing low traveler sales, several months without active UK distribution and no product remaining on the UK market. It will not appeal, citing the decision’s immaterial financial and commercial impact and its strategic focus on expanding access in endemic territories. In Brazil’s pilot vaccination strategy, more than 61,000 people aged 18–59 had been vaccinated without new safety concerns identified; approximately 187,000 IXCHIQ doses had been administered globally.
Valneva SE reported weak first-half 2026 results as it advances a focused vaccine portfolio and restructures operations. Total revenues were €65.8 million, down sharply from €97.6 million a year earlier, mainly due to the planned wind-down of third‑party sales, timing of IXIARO deliveries to the U.S. Department of Defense, distributor changes in Germany, and non‑recurring outbreak‑related sales in 2025 that did not repeat.
Product sales fell to €64.0 million, led by IXIARO/JESPECT at €44.0 million and DUKORAL at €14.7 million, while IXCHIQ contributed €4.4 million. One‑time IXCHIQ manufacturing contract cancellation fees of €9.7 million and a €4.5 million inventory impairment drove IXCHIQ to a strongly negative gross margin and cut group gross profit to €6.3 million.
Operating loss widened to €49.9 million and net loss to €63.3 million, versus €20.8 million a year earlier, with Adjusted EBITDA at –€40.1 million. Cash and cash equivalents rose to €121.5 million at June 30, 2026, supported by a reserved offering of up to €84 million in equity and warrants and ongoing cost reductions, including a planned 10–15% global workforce cut.
Strategically, Valneva and Pfizer reported Phase 3 VALOR data for Lyme vaccine candidate LB6V, showing more than 70% efficacy but not meeting a pre‑specified statistical criterion in the first primary analysis; Pfizer plans regulatory submissions. IXCHIQ remains approved in Europe, Canada, the UK and Brazil, with a Brazilian pilot vaccination campaign exceeding 50,000 adults and local manufacture authorized, but the U.S. BLA was voluntarily withdrawn after FDA license suspension linked to serious adverse events, increasing regulatory and commercial risk.
Valneva SE plans to report its first half 2026 financial results on August 13, 2026, and will host a live webcast at 3 p.m. CET / 9 a.m. ET to discuss the results and provide a business update, with an archived replay available on its website.
The company describes itself as a specialty vaccine business focused on prophylactic vaccines for infectious diseases with unmet medical needs. It currently markets three proprietary travel vaccines and is advancing a pipeline that includes a Lyme disease vaccine candidate partnered with Pfizer and a clinically advanced Shigella vaccine candidate.
Valneva SE reported that shareholders approved all Board-recommended resolutions at its Annual General Meeting in Lyon. Key decisions included approval of the 2025 financial statements, renewal of share capital authorizations and the transfer of the company’s registered office to Lyon.
Shareholders reappointed five directors with staggered terms, and the Board subsequently named independent director Dr. Gerd Zettlmeissl as Chair. Former Chair Anne‑Marie Graffin will remain on the Board as Vice-chair, while Valneva continues to focus on its portfolio of specialty travel and infectious disease vaccines.
Valneva SE is registering the resale of 31,609,140 ordinary shares (which may be represented by ADSs), consisting of 15,715,323 issued ordinary shares and 15,893,817 ordinary shares issuable upon exercise of ABSA warrants. The resale is being registered to satisfy the company’s registration‑rights obligations and the company will not receive proceeds from sales by the selling securityholders, except to the extent ABSA Warrants are exercised for cash. The prospectus states the ABSA Warrants may yield up to €47 million in cash proceeds if fully exercised. The prospectus also discloses a Beneficial Ownership Limitation (default 9.99%, adjustable up to 19.99% or higher subject to French FDI approval). Shares outstanding were 189,771,237 ordinary shares as of May 31, 2026.
Valneva SE has made the documentation for its Annual General Meeting on June 25, 2026 available to shareholders. The meeting will be held in Lyon, France, at 2:00 p.m. CEST at the Sofitel Lyon Bellecour Hotel.
Shareholders can access the agenda, draft resolutions, and voting instructions on Valneva’s website, or request them by email in line with French Commercial Code rules. Bearer shareholders must provide a shareholding certificate. The company also reiterates its focus on specialty vaccines and includes standard forward-looking statement cautions.